OncoMatch/Clinical Trials/NCT05493215
Imatinib TDM in GIST
Is NCT05493215 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Imatinib for gastrointestinal stromal tumors.
Treatment: Imatinib — Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
KIT mutation
Required: PDGFRA mutation
PDGFRA mutation (non-D842V)
Excluded: PDGFRA D842V
Presence of PDGFRA D842V mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
normal organ function
Kidney function
normal organ function
Liver function
normal organ function
Normal organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Markey Cancer Center · Lexington, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05493215 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KIT?
Yes, KIT mutation is a required biomarker for enrollment.
Does this trial require PDGFRA?
Yes, PDGFRA mutation is a required biomarker for enrollment.
Are patients with PDGFRA alterations eligible?
No. PDGFRA D842V is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify